Tharimmune (THAR) director Sommers files Form 3 reporting no holdings

Rhea-AI Filing Summary

Tharimmune, Inc. director Jill E. Sommers filed a Form 3 reflecting her status as a director and indicating that she beneficially owns no securities of Tharimmune. The filing is dated for an event on January 30, 2026 and is filed by one reporting person.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sommers Jill E.

(Last) (First) (Middle)

8711 EAGLEBROOK COURT

(Street)

ALEXANDRIA VA 22308

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/30/2026

3. Issuer Name and Ticker or Trading Symbol
Tharimmune, Inc. [ THAR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jill E. Sommers	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Tharimmune (THAR) disclose in this Form 3 filing?

Tharimmune’s Form 3 shows director Jill E. Sommers reporting that she beneficially owns no securities of Tharimmune. The filing relates to an event dated January 30, 2026 and is filed by a single reporting person.

Who is the reporting person in Tharimmune (THAR)’s latest Form 3?

The reporting person is Jill E. Sommers, identified as a director of Tharimmune, Inc. She indicates in the filing that she has no beneficial ownership of Tharimmune securities as of the reported event date of January 30, 2026.

Does the Tharimmune (THAR) Form 3 show any shares owned by the director?

No. The Form 3 explicitly states in the explanation section that no securities are beneficially owned. Both the non-derivative and derivative securities tables contain no reported holdings for director Jill E. Sommers in Tharimmune, Inc.

What is the event date reported in Tharimmune (THAR)’s Form 3 for director Sommers?

The Form 3 lists January 30, 2026 as the date of the event requiring the statement. As of that date, director Jill E. Sommers reports that she has no beneficial ownership of any Tharimmune, Inc. securities.